微信二维码

Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance N

  • 2021年05月06日
  • Author edit: mf123456

Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA) Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, announced the closing of an oversubscribed $105 Million Series B financing. With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ecDNA Harboring Oncogenes (ECHO™) companion diagnostics and expand its pipeline of novel cancer therapies targeting ecDNA.

More ›

Exscientia, with its World’s first AI-Designed Immuno-Oncology Drug to Enter Cli

  • 2021年05月06日
  • Author edit: mf123456

Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2 led the Series D and was joined by previous round lead investors, Novo Holdings, GT Healthcare Capital and funds managed by Blackrock. Funding from the Series D round will be used to advance Exscientia’s proprietary pipeline through clinical testing as well as to continue expanding the technology platform toward autonomous drug design. In addition, SoftBank is providing an additional $300 million equity commitment that can be drawn at the Company’s discretion.

More ›

Exscientia completes Series C financing round with BlackRock funds

  • 2021年03月05日
  • Author edit:

Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, today announced that funds managed by BlackRock joined the Company’s Series C investment round. The existing Series C investors also include Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital.

More ›

Immunocore raises $258m in NASDAQ IPO

  • 2021年02月08日
  • Author edit:

Immunocore’s upsized initial public offering in NASDAQ of 9,935,896 American Depositary Shares (“ADSs”) representing 9,935,896 ordinary shares at an initial public offering price of $26.00 per ADS, for total gross proceeds of approximately $258 million. The first day’s closing price jumps 66.15% to $43.2 per ADS, which represents a market cap of $1.796B. Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease - designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Immunocore's most advanced oncology therapeutic candidate, tebentafusp, demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma.

More ›

GI Windows raises $16.4M

  • 2020年08月20日
  • Author edit:

Anastomoses technology developer GI Windows Medical announced that it raised $16.4 million in a Series A-1 financing round. West Bridgewater, Mass.-based GI Windows said in a news release that Johnson &. Johnson Innovation, Sonder Capital, GT Healthcare, JC Investco and an additional strategic investor contributed to the funding round. In addition to the institutional financing, GI Windows said it received investments from existing shareholders, along with new investors, the Kennedy Trust and Coleman Trust. The company is earmarking the proceeds from the financing for further product development and clinical studies for its technology.

More ›